k-rasg12c inhibitors allosterically control gtp affinity effector interactions
somatic mutations small gtpase k-ras common activating lesions found human cancer generally associated poor response standard therapies- efforts target oncogene directly faced difficulties owing picomolar affinity gtp/gdp absence known allosteric regulatory sites oncogenic mutations result functional activation ras family proteins impairing gtp hydrolysis diminished regulation gtpase activity nucleotide state ras becomes dependent relative nucleotide affinity concentration gives gtp advantage gdp increases proportion active gtp-bound ras report development small molecules irreversibly bind common oncogenic mutant k-rasg12c compounds rely mutant cysteine binding therefore affect wild-type protein crystallographic studies reveal formation new pocket apparent previous structures ras beneath effector binding switch-ii region binding inhibitors k-rasg12c disrupts switch-i switch-ii subverting native nucleotide preference favour gdp gtp impairing binding raf data provide structure-based validation new allosteric regulatory site ras targetable mutant-specific manner
